3-chloro-L-tyrosine has been researched along with Atrial Fibrillation in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrié, RP; Baldus, S; Böger, RH; Didié, M; Ehmke, H; Eschenhagen, T; Freeman, BA; Friedrichs, K; Fu, X; Hazen, SL; Hirsch-Hoffmann, B; Klingel, K; Klinke, A; Lau, D; Lewalter, T; Meinertz, T; Nickenig, G; Reichenspurner, H; Rudolph, TK; Rudolph, V; Schrickel, JW; Schwoerer, AP; Seniuk, A; Sydow, K; Szoecs, K; Treede, H; von Leitner, EC; Wenzel, U; Willems, S; Zimmermann, WH | 1 |
1 other study(ies) available for 3-chloro-L-tyrosine and Atrial Fibrillation
| Article | Year |
|---|---|
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation.
Topics: Angiotensin II; Animals; Atrial Fibrillation; Heart Atria; Humans; Lymphocyte Activation; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Neutrophils; Peroxidase; Tyrosine | 2010 |